Skip to main content

CAMS to launch IPO on September 21; NSE to divest over 37% via public offer

 The offer for sale indicated that the NSE Investments is going to offload its almost entire stake in CAMS via IPO.

Computer Age Management Services (CAMS), the largest registrar and transfer agent of mutual funds, will open its initial public offering on September 21, according to the RHP. The anchor investors' book will open for a day on September 18.

The maiden public issue consists of an offer for sale of 1,82,46,600 equity shares by NSE Investments. The offer also includes a reservation of 1,82,500 equity shares for eligible employees.

The public offer, which would constitute at least 37.40 percent of post-offer paid-up equity capital of the company, will close on September 23.

The offer for sale indicated that the NSE Investments is going to offload its entire stake in CAMS via IPO.



In compliance with the requirements of the Sebi Letter, NSE intends to divest its entire shareholding, held through NSE Investments, in CAMS by way of sale and transfer of (i) 1,82,46,600 equity shares pursuant to the offer; and (ii) the balance 38,400 Equity Shares pursuant to the NSE Investments SPA (share purchase agreement), as per its red herring prospectus filed with Sebi on September 11.

NSEIL (the subsidiary of National Stock Exchange) held 37.48 percent stake in CAMS, HDFC 5.99 percent, HDFC Bank 3.33 percent, HDFC Trust 3.19 percent, Faering Capital India 4 percent and Acsys 1.94 percent, as per the draft red herring prospectus filed with the Sebi in January 2020.

Great Terrain, the wholly owned by Harmony River Investment, is the promoter of CAMS with 43.53 percent shareholding. Harmony River Investment is owned by private equity funds managed by US-based Warburg Pincus.

Great Terrain has, pursuant to the Great Terrain SPAs, agreed to sell and transfer 61,08,400 equity shares, prior to the bid/offer opening date. After such transfer, Great Terrain will hold 1,51,15,600 equity shares, i.e. 30.98 percent of the pre-offer and post-offer paid-up capital.

These shares will be transferred by NSE Investments (38,400 shares) and Great Terrain (61,08,400 shares) at Rs 1,230 per equity share, to insurance companies and mutual funds, as per the RHP.

According to people familiar with the IPO development, the higher end of IPO price band could be Rs 1,250 per share and the issue size approximately Rs 2,258 crore, while one can bid for minimum 12 equity shares and in multiples of 12 equity shares thereafter.

Chennai-headquartered CAMS is a technology-driven financial infrastructure and services provider to mutual funds and other financial institutions with over two decades of experience. The company is India's largest registrar and transfer agent of mutual funds with an aggregate market share of approximately 70 percent based on mutual fund average assets under management (AAUM) managed by its clients and serviced by them during July 2020.

This would be fifth IPO after Rossari Biotech, Mindspace Business Parks REIT, Happiest Minds Technologies and Route Mobile, to be launched in 2020. Chemcon Speciality Chemicals could also launch its initial public offering on September 21, sources told Moneycontrol.

Equity shares are proposed to be listed on the BSE.

Kotak Mahindra Capital Company, HDFC Bank, ICICI Securities and Nomura Financial Advisory and Securities (India) are the book running lead managers to the issue. Link Intime India is the registrar to the issue.

Labels:

Comments

Post a Comment

Popular posts from this blog

Panacea Biotech shares hit 5% upper circuit after dengue vaccine completes phase I & II study

DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes, the company has said in an exchange filing. Panacea Biotech share price hit 5 percent upper circuit on the BSE on September 24 after the company completed phases I and II study of its dengue vaccine candidate DengiAIl. "Panacea Biotec Ltd. is delighted to announce the successful completion of its Phase I/II study to evaluate the safety and immunogenicity of its vaccine, DengiAll, a single-dose liveattenuated tetravalent vaccine," the company said in an exchange filing. Live-attenuated vaccines contain weakened bacteria or viruses that trigger an immune response but do not cause disease. The company said DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes. DengiAIl has been found to be safe and well-tolerated with no serious adverse effects, the company said. After a single-dose, more than 80 percent of the participants ...
Post a Comment
Read more

Taking Stock | Profit-booking pulls Nifty below 14,450; Sensex drops 549 points

  All the sectoral indices ended in the red with IT and PSU bank indices falling 2 percent each. The market remained under pressure on January 15 on the back of profit-booking across sectors amid weak global cues. At close, the Sensex was down 549.49 points or 1.11% at 49,034.67, and Nifty was down 161.90 points or 1.11% at 14,433.70. "The market witnessed profit-booking and following global trends. Nifty continues to resist 14,600 and has taken a dip towards 14,360. If the market closes below 14,380 levels, we might see a correction till the levels of 14,180-14,200. Momentum indicators like RSI, MACD are indicating a small correction in the markets," said Ashis Biswas, Head of Research at CapitalVia Global Research. All the sectoral indices ended in the red with IT and PSU bank falling 2 percent each. Broader markets performed in line with the main indices with BSE Midcap and Smallcap indices falling 1 percent each. Tech Mahindra, GAIL, HCL Tech, Wipro and ONGC...
Post a Comment
Read more

Similar to 2020, D-Street is at record high ahead of Budget 2021; will history repeat itself?

  Experts are of the view that a repeat of 2020 or what happened in March might not be possible but some consolidation cannot be ruled out. Back in March when everyone wanted to write-off 2020 from their books, hope and liquidity supported markets and investor sentiment. Nobody thought that after touching a 3-year low in March 2020, benchmark indices would give double-digit returns by the end of the year. The S&P BSE Sensex and Nifty50 rallied by about 15 percent in 2020 and the big outperformance came from the small and midcap stocks. The rally is still continuing in 2021. The S&P BSE Sensex, which climbed Mount 49K, is up over 3 percent while the Nifty50 is up over 4 percent so far in January. Sensex scaling the 49,000-mark and Nifty50 touching 14,500 levels ahead of the Budget 2021 could make anyone cautious about the strength of the rally. Back in January 2020, both Sensex and Nifty touched fresh highs ahead of Budget, and then the market fell like a pack of cards. The ...
Post a Comment
Read more